Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved
Tetsuya Suzuki,
Yusuke Asai,
Kozue Takahashi,
Mio Sanada,
Yumiko Shimanishi,
Mari Terada,
Lubna Sato,
Makoto Inada,
Gen Yamada,
Yutaro Akiyama,
Yusuke Oshiro,
Katsuyuki Shiratori,
Tomiteru Togano,
Yuki Takamatsu,
Maeda Kenji,
Akihiro Matsunaga,
Yukihito Ishizaka,
Hidetoshi Nomoto,
Noriko Iwamoto,
Sho Saito,
Satoshi Kutsuna,
Shinichiro Morioka,
Norio Ohmagari
Affiliations
Tetsuya Suzuki
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan
Yusuke Asai
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
Kozue Takahashi
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Graduate School of Public Health, Teikyo University, Tokyo, Japan
Mio Sanada
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
Yumiko Shimanishi
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
Mari Terada
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
Lubna Sato
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
Makoto Inada
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
Gen Yamada
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
Yutaro Akiyama
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
Yusuke Oshiro
Clinical Laboratory Department, National Center for Global Health and Medicine, Tokyo, Japan
Katsuyuki Shiratori
Clinical Laboratory Department, National Center for Global Health and Medicine, Tokyo, Japan
Tomiteru Togano
Department of Hematology, National Center for Global Health and Medicine, Tokyo, Japan
Yuki Takamatsu
Department of Refractory Viral Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
Maeda Kenji
Department of Refractory Viral Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan
Akihiro Matsunaga
Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
Yukihito Ishizaka
Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
Hidetoshi Nomoto
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan
Noriko Iwamoto
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
Sho Saito
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
Satoshi Kutsuna
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Department of Infection Control, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan
Shinichiro Morioka
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan; Corresponding author. Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan
Norio Ohmagari
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
Background: We aimed to investigate chronological changes in the characteristics of participants in a coronavirus disease 2019 convalescent plasma donation study that may benefit optimal collection methods in the future. Methods: Data from a convalescent plasma donation study from April 30, 2020 to November 5, 2021 were collected and analyzed. After August 23, 2021, an interim analysis of factors linked to higher antibody titers led us to restrict our participant recruitment criteria to participants who were within 4 months of disease onset and to patients who were otherwise most likely to have sufficiently high antibody titers. Overall, 1299 samples from 1179 patients were analyzed. Results: Over the duration of the study, 35.9% of the samples were deemed eligible for convalescent plasma collection. The overall eligibility rate initially declined, dipping to 120 days post disease onset increased. After the addition of days from onset and vaccination status to our participant recruitment criteria, the eligibility rate improved significantly. Conclusions: As outbreaks of emerging infectious disease occur, it is desirable to construct and implement a scheme for convalescent plasma donation promptly and to monitor the eligibility rate over time. If it declines, promptly analyze and resolve the associated factors. Additionally, vaccine development and infection prevalence are likely to influence the effective recruitment of participants with high antibody titers.
